Andrew F Alexis, MD, MPH

This segment of the most recent episode of Skin of Color Savvy highlights a conversation between Shawn Kwatra, MD, and Andrew Alexis, MD, MPH.

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

Alexis spoke in this segment of his Fall Clinical interview on takeaways from his presentation titled ‘Melasma and Other Hyperpigmentation Disorders.’

In this Fall Clinical interview, Alexis highlights several tips for clinicians covered in his session at the conference titled ‘30 Tips in 30 Minutes.’

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights the unique clinical challenges of high-impact areas of psoriasis such as the scalp and hands.

Andrew Alexis, MD, MPH, highlights his ‘What’s New’ talk at AAD 2025 on new practices for treating pigmentary disorders such as vitiligo.

This interview with Andrew Alexis, MD, MPH, features some of the most notable highlights from his AAD 2025 talks on therapeutic and diagnostic pearls for skin of color.

In the inaugural episode of Skin of Color Savvy, Andrew Alexis, MD, MPH, and Shawn Kwatra, MD, discuss diagnosis and management of itch in skin of color.

This publication was developed independently by MJH Life Sciences Global Medical Affairs. Support for the thought leaders meeting and the publication was provided by Arcutis Biotherapeutics, Inc; The Bristol Myers Squibb Company; Janssen Global Services, LLC; and UCB, Inc.